Dupilumab for the treatment of adult atopic dermatitis in special populations

References

• Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136–1143.
   PubMed Web of Science ®Google Scholar
• Patruno C, Fabbrocini G, Napolitano M. Clinical phenotypes of atopic dermatitis of the adult. Ital J Dermatol Venerol. 2021;156(6):721–722.
   PubMedGoogle Scholar
• David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Di Guida A, Nocerino M, et al. The emerging role of dupilumab in dermatological indications. Expert Opin Biol Ther. 2021;21(11):1461–1471.
   PubMed Web of Science ®Google Scholar
• Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958–964.
   PubMed Web of Science ®Google Scholar
• DUPIXENT [Summary of Product Characteristics]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_it.pdf.
   Google Scholar
• Burkholder DM, Nash NB. Special populations in health care, 1st ed. Burlington: Jones & Bartlett Learning; 2013.
   Google Scholar
• Davies EA, O’Mahony MS. Adverse drug reactions in special populations – the elderly. Br J Clin Pharmacol. 2015;80(4):796–807.
   PubMed Web of Science ®Google Scholar
• Patruno C, Fabbrocini G, Longo G, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581–586.
   PubMed Web of Science ®Google Scholar
• Grimsrud KN, Sherwin CMT, Constance JE, et al. Special population considerations and regulatory affairs for clinical research. Clin Res Regul Aff. 2015;32(2):47–56.
   PubMedGoogle Scholar
• Siliquini N, Giura MT, Viola R, et al. Atopic dermatitis, dupilumab and cancers: a case series. J Eur Acad Dermatol Venereol. 2021;35(10):e651–2–e652.
   Web of Science ®Google Scholar
• Qiu Y, Ali K, Lou H, et al. Successful treatment of atopic dermatitis with dupilumab in a patient with Non-Hodgkin’s lymphoma. Acta Derm Venereol. 2022;102:adv00625.
   PubMed Web of Science ®Google Scholar
• Maglie R, Ugolini F, De Logu F, et al. Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy. J Eur Acad Dermatol Venereol. 2021;35(8):e501–3–e503.
   Web of Science ®Google Scholar
• Steck O, Bertschi NL, Luther F, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol. 2021;35(6):1331–1337.
   PubMed Web of Science ®Google Scholar
• Lazaridou I, Ram-Wolff C, Bouaziz J-D, et al. Dupilumab treatment in two patients with cutaneous T-cell lymphomas. Acta Derm Venereol. 2020;100(16):adv00271.
   PubMedGoogle Scholar
• Fowler E, Rosen J, Lev-Tov H, et al. Two cancer patients receiving dupilumab for treatment of atopic dermatitis. Acta Derm Venereol. 2019;99(10):899–900.
   PubMed Web of Science ®Google Scholar
• Avallone G, Trunfio M, Giura MT, et al. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review. Dermatol Online J. 2021;27(8):709.
   Google Scholar
• Nusbaum KB, Kaffenberger BH, Paradiso Bs MM, et al. Dupilumab for treatment of atopic dermatitis in patients living with HIV: a case series. Int J Dermatol. 2021;60(9):e344–6–e346.
   Web of Science ®Google Scholar
• Ordóñez-Rubiano MF, Rubiano-Mojica PC, Casas M. Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis. Int J Dermatol. 2021;60(4):514–515.
   PubMed Web of Science ®Google Scholar
• Olbricht N, Kromer C, Forkel S, et al. Effective treatment of atopic dermatitis with dupilumab in an HIV-positive patient. J Dtsch Dermatol Ges. 2020;18(12):1488–1490.
   Google Scholar
• Lor M, Villa N, Holland V. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV. Dermatol Ther. 2020;33(6):e14271.
   PubMed Web of Science ®Google Scholar
• Brodska P, Panzner P, Sedlacek D, et al. Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection. Dermatol Ther. 2020;33(6):e14159.
   PubMed Web of Science ®Google Scholar
• Romagnuolo M, Angileri L, Tavecchio S, et al. Safety and efficacy of dupilumab in a patient with severe atopic dermatitis and HIV infection, with 15 months of follow-up. Clin Exp Dermatol. 2020;45(6):762–763.
   PubMed Web of Science ®Google Scholar
• Tanner JF, Knutsen AP, Siegfried E. Safety and efficacy of dupilumab in an atopic adolescent with primary immune deficiency. Dermatitis. 2021;32(1S):e91–2–e92.
   Web of Science ®Google Scholar
• Ly K, Smith MP, Thibodeaux Q, et al. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Rep. 2019;5(7):624–626.
   PubMedGoogle Scholar
• Bianchelli T, Campanati A, Sapigni C, et al. The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report. Acta Dermatovenerol Alp Pannon. 2021;30(2):71–73.
   PubMed Web of Science ®Google Scholar
• Jamgochian M, Milgraum D, Milgraum S, et al. Dupilumab as treatment for atopic dermatitis in a pediatric heart transplant patient: a case report. Dermatol Ther. 2020;33(6):e14018.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Nocerino M, Picone V, et al. Dupilumab for the treatment of atopic dermatitis in transplant patients: two case reports and literature review. Dermatol Ther. 2022;35(4):e15324.
   PubMed Web of Science ®Google Scholar
• Kha C, Raji K, Chisolm S. Treatment of atopic dermatitis with dupilumab in a renal transplant patient. Dermatitis. 2020;31(2):e17–8–e18.
   Web of Science ®Google Scholar
• Elamin S, Murphy B. Dupilumab in the management of atopic dermatitis in an immunosuppressed renal transplant patient. Clin Experimental Derm. 2022;47(6):1191–1193.
   PubMed Web of Science ®Google Scholar
• Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):adv00161.
   PubMed Web of Science ®Google Scholar
• Patruno C, Stingeni L, Fabbrocini G, et al. Dupilumab and COVID-19: What should we expect? Dermatol Ther. 2020;33(4):e13502.
   PubMed Web of Science ®Google Scholar
• Stingeni L, Hansel K, Antonelli E, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther. 2021;34(5):e15035.
   PubMed Web of Science ®Google Scholar
• Potestio L, Napolitano M, Bennardo L, et al. Atopic dermatitis exacerbation after Covid-19 vaccination in dupilumab-treated patients. Acad Dermatol Venereol. 2022;36(6):e409–e411.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Talamonti M, De Simone C, et al. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. Allergy. 2021;76(6):1813–1824.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Patruno C, Ruggiero A, et al. Safety of dupilumab in atopic patients during COVID-19 outbreak. J Dermatolog Treat. 2022;33(1):600–601.
   PubMed Web of Science ®Google Scholar
• Colonna C, Zussino M, Monzani NA, et al. Treatment of children from 6 to 11 years old affected by moderate-severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy. Acad Dermatol Venereol. 2022;36(6):e478–e480.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Scalvenzi M, et al. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol. 2020;45(7):888–890.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Lam M, Flohr C, et al. Systemic therapy for atopic dermatitis in older adults and adults with comorbidities: a scoping review and international eczema council survey. Dermatitis. 2022;33(3):200.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Potestio L, et al. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Dermatol Ther. 2022;2022:e15588.
   Google Scholar